MY142067A - Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease - Google Patents

Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease

Info

Publication number: MY142067A
Authority: MY; Malaysia
Prior art keywords: derivatives; hm74a; activation; diseases; disease
Prior art date: 2005-08-10

Application number

MYPI20063833A

Other languages

English (en)

Inventor

Richard Jonathan Daniel Hatley

Andrew Mcmurtrie Mason

Ivan Leo Pinto

Original Assignee

Glaxosmithkline Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-08-10

Filing date

2006-08-08

Publication date

2010-08-30

2005-08-10 Priority claimed from GB0516464A external-priority patent/GB0516464D0/en

2006-04-19 Priority claimed from GB0607736A external-priority patent/GB0607736D0/en

2006-07-21 Priority claimed from GB0614569A external-priority patent/GB0614569D0/en

2006-08-08 Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc

2010-08-30 Publication of MY142067A publication Critical patent/MY142067A/en

Links

201000010099 disease Diseases 0.000 title abstract 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title abstract 2
229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 title abstract 2
238000004519 manufacturing process Methods 0.000 title abstract 2
238000000034 method Methods 0.000 title abstract 2
239000000556 agonist Substances 0.000 title 1
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
101000843809 Homo sapiens Hydroxycarboxylic acid receptor 2 Proteins 0.000 abstract 1
102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
230000009286 beneficial effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

MYPI20063833A 2005-08-10 2006-08-08 Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease MY142067A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0516464A GB0516464D0 (en)	2005-08-10	2005-08-10	Novel compounds
GB0607736A GB0607736D0 (en)	2006-04-19	2006-04-19	Novel compounds
GB0614569A GB0614569D0 (en)	2006-07-21	2006-07-21	Novel compounds

Publications (1)

Publication Number	Publication Date
MY142067A true MY142067A (en)	2010-08-30

Family

ID=37189397

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MYPI20063833A MY142067A (en)	2005-08-10	2006-08-08	Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease

Country Status (28)

Country	Link
US (3)	US20100179128A1 (2)
EP (3)	EP1912992A1 (2)
JP (2)	JP2009504592A (2)
KR (2)	KR20080038396A (2)
AR (1)	AR055369A1 (2)
AT (1)	ATE487719T1 (2)
AU (2)	AU2006278215A1 (2)
BR (2)	BRPI0615145A2 (2)
CA (2)	CA2618963A1 (2)
CR (2)	CR9749A (2)
CY (1)	CY1111757T1 (2)
DE (1)	DE602006018151D1 (2)
DK (1)	DK1912991T3 (2)
EA (2)	EA014556B1 (2)
ES (1)	ES2401128T3 (2)
HR (1)	HRP20100725T1 (2)
IL (2)	IL189081A0 (2)
MA (2)	MA29692B1 (2)
MX (2)	MX2008001931A (2)
MY (1)	MY142067A (2)
NO (2)	NO20081211L (2)
NZ (1)	NZ565494A (2)
PE (1)	PE20070405A1 (2)
PL (1)	PL1912991T3 (2)
PT (1)	PT1912991E (2)
SI (1)	SI1912991T1 (2)
TW (1)	TW200800217A (2)
WO (2)	WO2007017262A1 (2)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7495005B2 (en) *	2002-08-22	2009-02-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, their preparation and their use in pharmaceutical compositions
PL1781657T3 (pl) *	2004-02-14	2013-08-30	Glaxosmithkline Ip Dev Ltd	Leki o aktywności wobec receptora HM74A
DE102004030502A1 (de)	2004-06-24	2006-01-12	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
ES2401128T3 (es) *	2005-08-10	2013-04-17	Glaxosmithkline Llc	Derivados de xantina como agonistas selectivos de HM74A
MX2009000170A (es)	2006-06-23	2009-01-23	Incyte Corp	Derivados de purinona como agonistas de hm74a.
MX2009000169A (es)	2006-06-23	2009-01-26	Incyte Corp	Derivados de purinona como agonistas de hm74a.
EP2061767B1 (de)	2006-08-08	2014-12-17	Sanofi	Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de)	2007-11-13	2009-07-23	Sanofi-Aventis Deutschland Gmbh	Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
UY31968A (es)	2008-07-09	2010-01-29	Sanofi Aventis	Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
DK2370440T3 (en)	2008-12-08	2014-12-08	Glaxosmithkline Llc	8-Chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dion2-amino-2- (hydroxymethyl) -1,3-propandiolanhydrat for the treatment of diseases
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
KR20120060207A (ko)	2009-08-26	2012-06-11	사노피	신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR101799429B1 (ko)	2010-05-03	2017-11-21	에스케이바이오팜 주식회사	신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
AU2011292285A1 (en) *	2010-08-16	2013-01-31	Boehringer Ingelheim International Gmbh	Oxadiazole inhibitors of leukotriene production
JP5828188B2 (ja) *	2010-09-23	2015-12-02	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ロイコトリエン産生のオキサジアゾール阻害剤
WO2012120056A1 (de)	2011-03-08	2012-09-13	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de)	2011-03-08	2016-06-01	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de)	2011-03-08	2015-06-24	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de)	2011-03-08	2014-12-17	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PE20142366A1 (es) *	2012-05-30	2015-01-10	Hoffmann La Roche	Compuestos triazolo como inhibidores de pde 10
CN107082782B (zh) *	2013-03-15	2020-03-20	海德拉生物科学有限责任公司	取代的黄嘌呤及其使用方法
JP6417401B2 (ja) *	2013-05-10	2018-11-07	ギリアドアポロ，エルエルシー	Ａｃｃ阻害剤及びその使用
AU2014262547A1 (en)	2013-05-10	2015-11-26	Gilead Apollo, Llc	ACC inhibitors and uses thereof
EP2994139B1 (en)	2013-05-10	2019-04-10	Gilead Apollo, LLC	Acc inhibitors and uses thereof
JP6417402B2 (ja)	2013-05-10	2018-11-07	ギリアドアポロ，エルエルシー	Ａｃｃ阻害剤及びその使用
CN105646492B (zh) *	2014-11-14	2019-04-09	中国医学科学院药物研究所	含五元芳杂环的取代黄嘌呤类化合物及其制备方法和用途
DE102017000359A1 (de)	2016-08-26	2018-03-01	Bihl+Wiedemann Gmbh	Diagnose-Repeater für AS-Interface Netze
WO2018162607A1 (en) *	2017-03-07	2018-09-13	F. Hoffmann-La Roche Ag	Oxadiazole transient receptor potential channel inhibitors
AU2019318209B2 (en)	2018-08-10	2025-09-25	Diapin Therapeutics, Llc	Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
CN112724141A (zh) *	2021-01-21	2021-04-30	南京艾美斐生物医药科技有限公司	一种gpr109a蛋白受体抑制剂及其制备和应用
US20250136587A1 (en) *	2022-02-03	2025-05-01	D. E. Shaw Research, Llc	N3-substituted uracil compounds as trpa1 inhibitors
JP2026503850A (ja) *	2023-01-30	2026-01-30	ディー．イー．ショウリサーチ，エルエルシー	Ｔｒｐａ１阻害剤としての二環式イミド化合物
AR133217A1 (es) *	2023-07-10	2025-09-10	De Shaw Res Llc	Inhibidores de trpa1 bicíclicos y monocíclicos

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2797220A (en) *	1954-12-02	1957-06-25	Univ Michigan	Substituted paraxanthines
GB8906792D0 (en) *	1989-03-23	1989-05-10	Beecham Wuelfing Gmbh & Co Kg	Treatment and compounds
IL100088A (en)	1990-11-21	1995-07-31	Smithkline Beecham Corp	FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8
WO1993016699A1 (en)	1992-02-21	1993-09-02	Smithkline Beecham Corporation	Tnf inhibitors
EP0584347B1 (en)	1992-03-04	2003-01-15	Cell Therapeutics, Inc.	Enantiomeric hydroxylated xanthine compounds
US6469017B1 (en) *	1998-01-16	2002-10-22	Cell Therapeutics, Inc.	Method of inhibiting interleukin-12 signaling
US6693105B1 (en) *	1992-11-16	2004-02-17	Cell Therapeutics, Inc.	Hydroxyl-containing compounds
US5804584A (en) *	1992-11-16	1998-09-08	Cell Therapeutics, Inc.	Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
US5473070A (en) *	1992-11-16	1995-12-05	Cell Therapeutics, Inc.	Substituted long chain alcohol xanthine compounds
IL109161A0 (en)	1993-03-31	1994-06-24	Cell Therapeutics Inc	Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en)	1993-04-05	1997-09-23	Cell Therapeutics, Inc.	Halogen, isothiocyanate or azide substituted xanthines
WO1994024133A1 (en)	1993-04-09	1994-10-27	Cell Therapeutics, Inc.	Ring-substituted cell signaling inhibitors
AU1868195A (en)	1994-01-28	1995-08-15	Cell Therapeutics, Inc.	Cell signaling inhibitors
JPH09511496A (ja)	1994-02-18	1997-11-18	セル・セラピューティックス・インコーポレーテッド	細胞内メッセンジャー
US6878715B1 (en) *	1994-02-18	2005-04-12	Cell Therapeutics, Inc.	Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US6780865B1 (en) *	1994-02-18	2004-08-24	Cell Therapeutics, Inc.	Compounds having selective hydrolytic potentials
US6103730A (en) *	1994-03-24	2000-08-15	Cell Therapeutics, Inc.	Amine substituted compounds
US5807861A (en) *	1994-03-24	1998-09-15	Cell Therapeutics, Inc.	Amine substituted xanthinyl compounds
US6323201B1 (en) *	1994-12-29	2001-11-27	The Regents Of The University Of California	Compounds for inhibition of ceramide-mediated signal transduction
AR015966A1 (es)	1997-10-17	2001-05-30	Smithkline Beecham Corp	Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
CA2369981A1 (en)	1999-04-09	2000-10-19	Cell Therapeutics, Inc.	Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
US20030207901A1 (en) *	1999-07-27	2003-11-06	Cell Therapeutics, Inc.	Hydroxyl-containing compounds
US6821978B2 (en)	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
US6586429B2 (en) *	2000-11-29	2003-07-01	Cell Therapeutics, Inc.	Tricyclic fused xanthine compounds and their uses
EP1368349B1 (de) *	2001-02-24	2007-02-14	Boehringer Ingelheim Pharma GmbH & Co.KG	Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
EP1377834A2 (en)	2001-04-11	2004-01-07	Glaxo Group Limited	Medicaments which are modulators of hm74 and/or hm74a activity
DE60225556D1 (de) *	2001-07-03	2008-04-24	Novo Nordisk As	Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
EP1338595B1 (en)	2002-02-25	2006-05-03	Eisai Co., Ltd.	Xanthine derivatives as DPP-IV inhibitors
US7482337B2 (en) *	2002-11-08	2009-01-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
CN1227492C (zh) *	2003-03-11	2005-11-16	张跃	一种吸收式空调主体
GB0319124D0 (en) *	2003-08-14	2003-09-17	Smithkline Beecham Corp	Chemical compounds
PL1781657T3 (pl) *	2004-02-14	2013-08-30	Glaxosmithkline Ip Dev Ltd	Leki o aktywności wobec receptora HM74A
KR20070070231A (ko) *	2004-10-22	2007-07-03	스미스클라인 비참 코포레이션	Ｈｍ７４ａ 수용체 활성을 가지는 크산틴 유도체
WO2006045564A1 (en) *	2004-10-22	2006-05-04	Smithkline Beecham Corporation	Xanthine derivatives with hm74a receptor activity
US20090209561A1 (en) *	2004-10-22	2009-08-20	Richard Jonathan Daniel Hatley	Xanthine Derivatives with HM74A Receptor Activity
JP2008530074A (ja) *	2005-02-14	2008-08-07	スミスクライン・ビーチャム・コーポレイション	Ｈｍ７４ａ受容体アゴニストとしてのアントラニル酸誘導体
GB0516462D0 (en) *	2005-08-10	2005-09-14	Smithkline Beecham Corp	Novel compounds
ES2401128T3 (es) *	2005-08-10	2013-04-17	Glaxosmithkline Llc	Derivados de xantina como agonistas selectivos de HM74A
DE102008009758A1 (de) *	2008-02-18	2009-08-20	Beiersdorf Ag	Verwendung von 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propan-1-on zur verbesserten Hautkonturierung bzw. gegen Cellulite
DK2370440T3 (en)	2008-12-08	2014-12-08	Glaxosmithkline Llc	8-Chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dion2-amino-2- (hydroxymethyl) -1,3-propandiolanhydrat for the treatment of diseases

2006
- 2006-08-08 ES ES10172674T patent/ES2401128T3/es active Active
- 2006-08-08 EA EA200800555A patent/EA014556B1/ru not_active IP Right Cessation
- 2006-08-08 NZ NZ565494A patent/NZ565494A/en not_active IP Right Cessation
- 2006-08-08 DE DE602006018151T patent/DE602006018151D1/de active Active
- 2006-08-08 DK DK06763016.0T patent/DK1912991T3/da active
- 2006-08-08 JP JP2008525475A patent/JP2009504592A/ja not_active Withdrawn
- 2006-08-08 CA CA002618963A patent/CA2618963A1/en not_active Abandoned
- 2006-08-08 SI SI200630916T patent/SI1912991T1/sl unknown
- 2006-08-08 AR ARP060103459A patent/AR055369A1/es unknown
- 2006-08-08 AU AU2006278215A patent/AU2006278215A1/en not_active Abandoned
- 2006-08-08 EP EP06776699A patent/EP1912992A1/en not_active Withdrawn
- 2006-08-08 WO PCT/EP2006/007869 patent/WO2007017262A1/en not_active Ceased
- 2006-08-08 PT PT06763016T patent/PT1912991E/pt unknown
- 2006-08-08 PL PL06763016T patent/PL1912991T3/pl unknown
- 2006-08-08 TW TW095128952A patent/TW200800217A/zh unknown
- 2006-08-08 EP EP06763016A patent/EP1912991B1/en not_active Not-in-force
- 2006-08-08 HR HR20100725T patent/HRP20100725T1/hr unknown
- 2006-08-08 US US12/063,432 patent/US20100179128A1/en not_active Abandoned
- 2006-08-08 EP EP10172674A patent/EP2272848B1/en active Active
- 2006-08-08 PE PE2006000963A patent/PE20070405A1/es not_active Application Discontinuation
- 2006-08-08 MX MX2008001931A patent/MX2008001931A/es active IP Right Grant
- 2006-08-08 BR BRPI0615145-0A patent/BRPI0615145A2/pt not_active Application Discontinuation
- 2006-08-08 KR KR1020087005724A patent/KR20080038396A/ko not_active Withdrawn
- 2006-08-08 AT AT06763016T patent/ATE487719T1/de active
- 2006-08-08 MY MYPI20063833A patent/MY142067A/en unknown
- 2006-08-08 AU AU2006278216A patent/AU2006278216A1/en not_active Abandoned
- 2006-08-08 CA CA002626723A patent/CA2626723A1/en not_active Abandoned
- 2006-08-08 MX MX2008001929A patent/MX2008001929A/es not_active Application Discontinuation
- 2006-08-08 WO PCT/EP2006/007865 patent/WO2007017261A1/en not_active Ceased
- 2006-08-08 KR KR1020087005717A patent/KR20080034993A/ko not_active Ceased
- 2006-08-08 EA EA200800564A patent/EA200800564A1/ru unknown
- 2006-08-08 BR BRPI0614270-2A patent/BRPI0614270A2/pt not_active IP Right Cessation
- 2006-08-08 JP JP2008525474A patent/JP5112316B2/ja not_active Expired - Fee Related
- 2006-08-08 US US12/063,434 patent/US8143264B2/en not_active Expired - Fee Related
2008
- 2008-01-28 IL IL189081A patent/IL189081A0/en unknown
- 2008-01-28 IL IL189083A patent/IL189083A0/en unknown
- 2008-02-08 MA MA30628A patent/MA29692B1/fr unknown
- 2008-02-08 MA MA30629A patent/MA29693B1/fr unknown
- 2008-02-21 CR CR9749A patent/CR9749A/es not_active Application Discontinuation
- 2008-02-21 CR CR9748A patent/CR9748A/es not_active Application Discontinuation
- 2008-03-07 NO NO20081211A patent/NO20081211L/no not_active Application Discontinuation
- 2008-03-07 NO NO20081212A patent/NO20081212L/no not_active Application Discontinuation
2011
- 2011-01-12 CY CY20111100033T patent/CY1111757T1/el unknown
- 2011-04-18 US US13/088,962 patent/US20110257205A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BRPI0614270A2 (pt)	2011-03-22
EA200800555A1 (ru)	2008-08-29
NO20081212L (no)	2008-05-06
NZ565494A (en)	2011-06-30
HRP20100725T1 (hr)	2011-01-31
WO2007017261A1 (en)	2007-02-15
DE602006018151D1 (de)	2010-12-23
CR9749A (es)	2008-05-22
AR055369A1 (es)	2007-08-22
US20100168122A1 (en)	2010-07-01
ATE487719T1 (de)	2010-11-15
PT1912991E (pt)	2011-01-17
PE20070405A1 (es)	2007-05-06
JP2009504591A (ja)	2009-02-05
MX2008001929A (es)	2008-03-24
EP1912991B1 (en)	2010-11-10
EA200800564A1 (ru)	2008-08-29
HK1116779A1 (en)	2009-01-02
BRPI0615145A2 (pt)	2009-11-03
EA014556B1 (ru)	2010-12-30
IL189083A0 (en)	2008-08-07
CY1111757T1 (el)	2015-10-07
US20110257205A1 (en)	2011-10-20
KR20080038396A (ko)	2008-05-06
PL1912991T3 (pl)	2011-04-29
US20100179128A1 (en)	2010-07-15
US8143264B2 (en)	2012-03-27
EP2272848A1 (en)	2011-01-12
JP5112316B2 (ja)	2013-01-09
MX2008001931A (es)	2008-03-24
JP2009504592A (ja)	2009-02-05
NO20081211L (no)	2008-05-08
WO2007017262A1 (en)	2007-02-15
MA29692B1 (fr)	2008-08-01
AU2006278215A1 (en)	2007-02-15
CA2626723A1 (en)	2007-02-15
TW200800217A (en)	2008-01-01
KR20080034993A (ko)	2008-04-22
DK1912991T3 (da)	2011-02-21
CR9748A (es)	2008-05-05
AU2006278216A1 (en)	2007-02-15
SI1912991T1 (sl)	2011-03-31
IL189081A0 (en)	2008-08-07
EP1912992A1 (en)	2008-04-23
ES2401128T3 (es)	2013-04-17
EP2272848B1 (en)	2012-12-26
MA29693B1 (fr)	2008-08-01
CA2618963A1 (en)	2007-02-15
EP1912991A1 (en)	2008-04-23

Publication	Publication Date	Title
MY142067A (en)	2010-08-30	Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease
MX2007004882A (es)	2007-05-09	Derivados de xantina con actividad de receptor de hm74a.
HRP20130406T1 (hr)	2013-06-30	Medikamenti s aktivnošä†u prema receptoru hm74a
TW200606162A (en)	2006-02-16	Pyrazolopyridine derivatives
IL184898A0 (en)	2007-12-03	Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
MX2009006704A (es)	2009-06-30	Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
UA104988C2 (uk)	2014-04-10	Похідні піроніндолу та спосіб їх отримання
TW200716646A (en)	2007-05-01	(S)-N-methylnaltrexone
TW200621730A (en)	2006-07-01	Chemical compounds
MX2009006345A (es)	2009-06-23	Compuestos utiles como inhibidores de proteina cinasa.
MXPA05008478A (es)	2005-10-18	Heterociclos sustituidos.
MX2007008924A (es)	2007-08-21	Compuestos quimicos.
WO2006058868A3 (de)	2006-08-03	Substituierte pteridine zur behandlung von entzündlichen erkrankungen
MY179527A (en)	2020-11-10	Catecholamine derivatives useful for the treatment of parkinson's disease
ATE470443T1 (de)	2010-06-15	Indol-1-yl-essigsäurederivate
EP2004637A1 (en)	2008-12-24	Substituted ring fused azines and their use in cancer therapy
WO2005016867A3 (en)	2005-03-31	Anthranilic acid derivatives and their use as activators of the hm74a receptor
MX2009006327A (es)	2009-06-23	Compuestos heterociclicos y metodos de uso de los mismos.
WO2009062576A8 (en)	2010-04-01	Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
TW200611695A (en)	2006-04-16	Pyrrolopyridine derivatives
UA86399C2 (ru)	2009-04-27	Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
MX2008001211A (es)	2008-03-24	Derivados de bencilpiperazina y su uso medico.
UA95780C2 (en)	2011-09-12	Xanthine derivatives as selective hm74a agonists
MY140543A (en)	2009-12-31	Heterocyclylamide-substituted imidazoles
TW200738611A (en)	2007-10-16	9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments